Last update: Feb. 27, 2018

Desloratadine

Very Low Risk for breastfeeding


Safe. Compatible.
Not risky for breastfeeding or infant.

Second generation anti-histaminic drug with low sedative effect.

Desloratadine es the active metabolite of loratadine. Its characteristics might be extrapolated to those of loratadine (So 2010).

Loratadine is excreted in non-significant amount into breast milk (Hilbert 1988). No side effects were observed in breastfed infants of treated mothers (Merlob 2002).

Various medical societies and expert consensus consider the use of loratadine safe during breastfeeding (So 2010, National Asthma Ed. 2004, Solhaug 2004, Ghaeli 1993).

The British Society of Immunology and Allergy rates loratadine compatible with breastfeeding (Powell 2007).

American Academy of Pediatrics: loratadine is a medication usually compatible with breastfeeding (AAP 2001).

The pharmacokinetic data of loratadine (higher percentage of protein binding, pKa acid and shorter half-life) would favor a lower excretion in breast milk.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Desloratadine is also known as


Desloratadine in other languages or writings:

Group

Desloratadine belongs to this group or family:

Tradenames

Main tradenames from several countries containing Desloratadine in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Alta - Hig %
Molecular weight 311 daltons
Protein Binding 82 - 87 %
pKa 9,7 -
Tmax 3 hours
T1/2 20 - 30 hours

References

  1. So M, Bozzo P, Inoue M, Einarson A. Safety of antihistamines during pregnancy and lactation. Can Fam Physician. 2010 May;56(5):427-9. Abstract Full text (link to original source) Full text (in our servers)
  2. Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PA, Nasser SM; British Society for Allergy and Clinical Immunology (BSACI). BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007 Abstract Full text (link to original source) Full text (in our servers)
  3. Solhaug V, Roland PD. Bruk av antihistaminer under graviditet og amming \ [Use of antihistaminics during pregnancy and breast feeding]. Tidsskr Nor Laegeforen. 2004 Abstract Full text (link to original source) Full text (in our servers)
  4. Merlob P, Stahl B. Prospective follow-up of adverse reactions in breast-fed infants exposed to loratadine treatment (1999-2001). BELTIS Newsl. 2002;Number 10:43-51 (in Lactmed) 2002 Full text (in our servers)
  5. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  6. Ghaeli P, Kaufman MB. Oral antihistamines/decongestants and breastfeeding. J Hum Lact. 1993 Abstract
  7. Hilbert J, Radwanski E, Affrime MB, Perentesis G, Symchowicz S, Zampaglione N. Excretion of loratadine in human breast milk. J Clin Pharmacol. 1988 Abstract

Total visits

177,475

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM